MAXISORB

INSTRUCTION
for medical use of medicinal product

MAXISORB

Composition:

active ingredient: silicon dioxide;

1 sachet contains 1 g of silicon dioxide;

1 jar contains 2 g of silicon dioxide;

1 bottle contains 12 g of silicon dioxide.

Pharmaceutical form. Powder for oral suspension.

Main physico-chemical properties: white or almost white, light, finely dispersed, amorphous powder.

Pharmacotherapeutic group.

Enter sorbents. ATC code A07B C.

Pharmacological properties.

Pharmacodynamics.

Sorbent agent. By adsorption binds and removes from the body toxins of exogenous and endogenous origin, food and bacterial allergens, microbial endotoxins, toxic products formed during protein breakdown in the intestine.

Pharmacokinetics.

The drug is practically not absorbed from the intestine.

Clinical characteristics.

Indications.

Acute intestinal diseases accompanied by diarrheal syndrome (salmonellosis, foodborne toxic infections); in complex therapy of viral hepatitis A and B.

Contraindications.

Individual hypersensitivity to the drug. Peptic ulcer of stomach and duodenum in the stage of exacerbation, ulcers and erosions of mucous membranes of small and large intestine, intestinal obstruction. Age under 1 year.

Interaction with other medicinal products and other types of interactions.

When the drug is used simultaneously with acetylsalicylic acid, platelet disaggregation is enhanced.

In complex therapy with nicotinic acid and simvastatin, Maxisorb exhibits synergistic action – promotes reduction of atherogenic lipid fractions in blood and increases high-density lipoprotein cholesterol levels.

Use of Maxisorb in intracorporeal sorption detoxification in combination with standard antiseptic solutions (bifuran, trifuran) increases treatment efficacy in purulent-inflammatory diseases.

Inform your doctor about concomitant use of any other medicinal products.

Special precautions.

Ingestion of the dry powder orally is prohibited.

Silicon dioxide should be taken 1 hour before meals or administration of other medicinal products due to the possibility of adsorption and, consequently, reduced efficacy.

Use during pregnancy or breastfeeding.

The medicinal product is not recommended for use during pregnancy or breastfeeding.

Ability to affect reaction speed when driving or operating machinery.

No effect.

Administration and dosage.

The drug is administered as an aqueous suspension taken orally 1 hour before meals or use of other medicinal products.

If the patient is unable to take the enterosorbent independently, the suspension is administered into the stomach through a tube.

To prepare the suspension, add 250 ml of cooled boiled water to the vial containing 12 g of the drug; 20 ml of the resulting suspension (one full tablespoon) contains approximately 1 g of the drug.

When using a smaller dose, the drug from a jar (2 g) or sachet (1 g) is poured into a glass, then cooled boiled water is added at a rate of 20 ml per 1 g of the drug, and gently shaken.

For children aged 1 to 7 years, the daily dose is 150–200 mg per 1 kg of body weight. The daily dose of the drug as a suspension should be divided into 3–4 doses.

The daily dose of the drug for adults and children aged 7 years and older is 12 g. The daily dose of the drug as a suspension should be divided into 3 doses.

The prepared suspension should be stored at 2 °C to 8 °C for no more than 24 hours.

In acute intestinal diseases, treatment should begin with the maximum single dose, not exceeding half of the daily dose. The treatment course is 3–5 days and, if necessary, may be extended to 10–15 days.

The treatment course for viral hepatitis at the above-mentioned doses is 7–10 days and depends on the severity of the disease.

Children.

Not recommended for children under 1 year of age.

Overdose.

No cases of overdose have been reported. When the drug is taken in excessive doses, difficulty with defecation may occur.

Adverse reactions.

In isolated cases, temporary constipation may occur.

If any adverse events occur, consult a physician!

Shelf life.

3 years.

The drug must not be used after the expiry date stated on the packaging.

Storage conditions.

Store at a temperature not exceeding 25 ºC in the original packaging.

Keep out of reach of children.

Packaging. 12 g in a bottle No. 1, 2 g in a jar No. 12, 1 g in sachets No. 24.

Prescription status.

Over-the-counter.

Manufacturer.

JSC "Biolyk".

Manufacturer's address.

131, Nezalezhnosti St., Ladizhin, Vinnytsia region, Ukraine, 24321.

Marketing Authorization Holder.

LLC "Ukrainian Pharmaceutical Company".

Address of the Marketing Authorization Holder.

1U Starosil'ska St., Kyiv, Ukraine, 02660.